Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
Progressie van MS volgen met biomarkers in het bloed
sep 2020 | Multipele Sclerose